Novartis P/E Ratio
Current P/E Ratio
48.58
High Valuation
Very High - High growth expectations or significantly overvalued
Novartis P/E ratio. Novartis (NOVARTIND) P/E ratio is 48.58 (High), EPS (TTM) ₹37.74, current price ₹1967.80 on NSE — Very High - High growth expectations or significantly overvalued. For live price, revenue and the complete fundamental profile, see NOVARTIND screener.
Current Valuation Metrics
P/E Ratio
48.58
Current Price
₹1967.80
EPS (TTM)
₹37.74
Exchange
NSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
56.27
Sector Median
31.61
Sector Rank
#11 of 199
Sector Percentile
5.5%
NOVARTIND P/E Ratio — Valuation Signal & Historical Context
Novartis P/E 48.58 — signal: Overvalued. Check Novartis marketcap in USD to track the company's total market size over time.
- Stock appears overvalued with PE of 48.58, suggesting caution for new investments
- Trading at discount to sector average PE of 56.27
NOVARTIND vs Healthcare Peers — P/E Ratio Comparison
Novartis P/E 48.58 vs Healthcare average 56.27, median 31.61 — range 2.04–740.29.
Sector Average
56.27
Sector Median
31.61
Lowest P/E
2.04
Highest P/E
740.29
Companies
199
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.04 | ₹65 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹63 | Low |
| Sun Pharma Advanced Rese… | SPARC | 3.98 | ₹6,206 | Low |
| Dipna Pharmachem | DPL | 4.57 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.88 | ₹66 | Low |
| GKB Ophthalmics | GKB | 5.88 | ₹32 | Low |
| Kabra Drugs | KABRADG | 6.09 | ₹44 | Low |
| Royal Sense | ROYAL | 6.58 | ₹47 | Low |
| Colinz Laboratories | COLINZ | 6.62 | ₹18 | Low |